EDAP TMS S.A. Confirms Strong Clinical Leadership on HIFU for the Treatment of Localized Prostate Cancer

EDAP TMS S.A. Confirms Strong Clinical Leadership on HIFU for the
Treatment of Localized Prostate Cancer
More Than 6,600 Ablatherm Treatments Procedures Performed to date Successful
Results at 8 Years to be Presented at the Next European Urology Congress 


LYON, France, Feb. 24  /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP),
today confirms its strong clinical leadership on HIFU technology using
Ablatherm(R).

EDAP continues to validate its clinical leadership position and credibility in
the High Intensity Focused Ultrasound (HIFU) treatment of localized prostate
cancer with more than 6,600 Ablatherm treatments performed to date. HIFU is now
widely recognized within the medical community as a solution for patients who
are not candidates for surgery or who failed radiotherapy treatment. In 2004,
more than 20 abstracts referring to the use of HIFU with Ablatherm were
presented by Urologists using Ablatherm at various international congresses.
Three articles were published in peer reviewed urological journals. For more
information, please feel free to visit our web site dedicated to HIFU with
Ablatherm   http://www.edap-hifu.com/.

EDAP continues to build its Ablatherm business and expand its market share
while benefiting from the support of key opinion leaders and urologists.

In line with the strategy to educate both patients and physicians regarding
HIFU with Ablatherm as a successful therapeutic option for patients suffering
from prostate cancer, EDAP will be actively participating in the next European
Association of Urology (EAU) meeting in Istanbul, Turkey, March 16-19, 2005
(Booth C17). Dr. S. Thuroff, from Harlaching Hospital, Munich, Germany, will be
presenting successful clinical results at eight years following Ablatherm
treatment. Dr. J. Lunz from Caritas Krankenhaus St Joseph Hospital, Regensburg,
Germany, will address the better quality of life obtained following Ablatherm
treatment compared to radical surgery. Dr. A. Gelet from Edouard Herriot
Hospital, Lyon, France, will present updated results obtained after the use of
HIFU with Ablatherm on patients who failed radiotherapy treatment. Three
additional abstracts referring to the use of Ablatherm will also be discussed
over the course of this conference.

Hugues de Bantel, Chief Executive Officer of EDAP TMS, commented: "We are very
pleased with the number of HIFU with Ablatherm treatments completed as of the
end of 2004. The increasing growth rates in Ablatherm treatment clearly confirm
our position as the leading provider in the field of HIFU treatment for
prostate cancer. With more than 230,000 new prostate cancer cases diagnosed
every year in the United States and more than 250,000 new cases in Europe, our
market scope is tremendous. We are positioning EDAP for rapid expansion and
market share growth. EDAP's strategy will include the continuing education of
both patients and physicians regarding HIFU with Ablatherm treatment options,
as well as developing our mobile business by offering a payment per procedure
performed model, to doctors and hospitals. We are also enthusiastic about our
results obtained on patients who failed radiotherapy treatment. With more than
300 treatments performed to date, HIFU with Ablatherm offers a unique curative
option to patients who are facing a therapeutic dead end. EDAP is presently
working to offer this solution to a wider range of patients facing similar
failures from prior treatment."

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically
proven choice for High Intensity Focused Ultrasound (HIFU) treatment of
localized prostate cancer. HIFU treatment is shown to be a minimally invasive
and effective treatment option with a low occurrence of side effects. The
company is also developing this technology for the treatment of certain other
types of tumors. EDAP TMS S.A. also produces and commercializes medical
equipment for treatment of urinary tract stones using Extra-corporeal Shockwave
Lithotripsy (ESWL).

For more information on the Company, contact the Investor Relations Dept by
phone at [phone] or see the Company's Web site at:
http://www.edap-tms.com/.

This press release contains, in addition to historical information,
forward-looking statements that involve risks and uncertainties. These include
statements regarding the Company's growth and expansion plans. Such statements
are based on management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ materially
from those described in the forward-looking statements. Factors that may cause
such a difference include, but are not limited to, those described in the
Company's filings with the Securities and Exchange Commission. 

DATASOURCE: EDAP TMS S.A.



CONTACT:  Hugues de Bantel, Philippe Chauveau, or Blandine Confort, all

of EDAP TMS S.A., [phone]; or Matt Kreps or Geralyn DeBusk, both of

Halliburton Investor Relations, [phone], for EDAP TMS S.A.



Web site:  http://www.edap-tms.com/

http://www.edap-hifu.com/ 

Copyright